Some of the highlights from the May issue include:
- The World Health Organisation (WHO) has published an updated classification of central nervous system tumours, setting a new standard for brain tumour research, diagnosis and communication..
- The US Food and Drug Administration (FDA) has given “breakthrough designation” to a poliovirus-based brain tumour immunotherapy, PVS-RIPO, for the treatment of recurrent glioblastoma.
- The 2016 / 2017 edition of the IBTA’s Brain Tumour magazine will be available for viewing online via the IBTA website from 8th June.
- A study has concluded that giving radiation therapy in ‘fractionated’ doses, rather than as a single larger dose, does not spare white matter from the late effects of radiation damage.
- Two published studies have investigated the potential link between mobile phone use and brain tumours: one finding that the increased rates of brain tumour diagnosis seen in recent years cannot be explained by mobile phone use, another finding that tumour formation was increased in mice exposed to mobile phone frequency radiation.
- Brain Tumor Awareness Month in the USA saw record numbers of people taking part and the Australian Brain Cancer Action Week saw various outreach, educational events and fund-raising activities take place across the country.
- Clinical trial results have shown that treatment with a cytomegalovirus (CMV) pp65 dendritic cell (DC) vaccine is linked to better than expected survival in glioblastoma patients.
- You can read the IBTA e-News April edition online here.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.
To see an archive of existing e-News issues, click here.